HCW Biologics (NASDAQ:HCWB) Trading Up 21.1% – Should You Buy?

HCW Biologics Inc. (NASDAQ:HCWB) was up 21.1% during trading on Wednesday . The stock traded as high as $4.88 and last traded at $4.88. Approximately 957,623 shares changed hands during trading, a decline of 26% from the average daily volume of 1,287,002 shares. The stock had previously closed at $4.03.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on HCWB shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a report on Wednesday. Wall Street Zen lowered HCW Biologics from a “hold” rating to a “sell” rating in a report on Friday, August 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $35.00.

HCW Biologics Stock Performance

The company has a market capitalization of $10.50 million, a price-to-earnings ratio of -0.35 and a beta of 0.62. The firm has a 50-day simple moving average of $4.37 and a two-hundred day simple moving average of $6.03.

HCW Biologics (NASDAQ:HCWB) last released its earnings results on Monday, August 18th. The company reported ($6.79) earnings per share for the quarter, missing the consensus estimate of $1.80 by ($8.59). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $7.00 million.

Hedge Funds Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Golden State Wealth Management LLC bought a new stake in HCW Biologics Inc. (NASDAQ:HCWB) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 10,000 shares of the company’s stock, valued at approximately $40,000. Golden State Wealth Management LLC owned approximately 0.69% of HCW Biologics at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.96% of the company’s stock.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.